Spyglass Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of chronic ophthalmic diseases through its innovative drug delivery platform. The company's primary focus is on addressing the challenges of patient compliance and the limitations of traditional eye drop therapies, which are often the standard of care for conditions like glaucoma. Spyglass Pharma's core technology is a proprietary drug-eluting intraocular lens (IOL) platform. This system is designed to be implanted during routine cataract surgery, providing a controlled, long-term release of medication directly into the eye. By automating drug delivery at the source, the company aims to provide a more consistent and effective treatment regimen for patients suffering from glaucoma and ocular hypertension, significantly reducing the burden of daily self-administration. The company's lead product candidate utilizes this platform to deliver bimatoprost, a well-established medication for lowering intraocular pressure, over an extended period. This approach seeks to eliminate the high rates of non-compliance associated with topical drops. Spyglass Pharma is currently advancing its platform through clinical trials to establish the safety and efficacy of its delivery system. Headquartered in Aliso Viejo, California, Spyglass Pharma was co-founded by industry veterans and clinicians with extensive experience in ophthalmology and medical device development. The company is supported by leading venture capital investors and continues to explore the application of its technology to a broader range of ocular conditions beyond its initial focus on glaucoma.